M
Michael Friedlander
Researcher at University of New South Wales
Publications - 518
Citations - 42914
Michael Friedlander is an academic researcher from University of New South Wales. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 78, co-authored 469 publications receiving 35099 citations. Previous affiliations of Michael Friedlander include University of Sydney & Peter MacCallum Cancer Centre.
Papers
More filters
Journal ArticleDOI
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Andrew Tutt,Mark E. Robson,Judy Garber,Susan M. Domchek,M. William Audeh,Jeffrey N. Weitzel,Michael Friedlander,Banu Arun,Niklas Loman,Rita K. Schmutzler,Andrew M Wardley,Gillian Mitchell,H. M. Earl,Mark Wickens,James Carmichael +14 more
TL;DR: Findings from this phase 2 study provide positive proof of concept of the efficacy and tolerability of genetically targeted treatment with olaparib in BRCA-mutated advanced ovarian cancer.
Journal ArticleDOI
Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry
TL;DR: There was a good correlation between the DNA histograms produced using this method and those obtained using unfixed tissue from the same tumor stained with ethidium bromide plus mithramycin.
Journal ArticleDOI
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Karoline Kuchenbaecker,Karoline Kuchenbaecker,John L. Hopper,Daniel R. Barnes,Kelly-Anne Phillips,T.M. Mooij,Marie-José Roos-Blom,Marie-José Roos-Blom,Sarah Jervis,Sarah Jervis,Flora E. van Leeuwen,Roger L. Milne,Roger L. Milne,Nadine Andrieu,David E. Goldgar,Mary Beth Terry,Matti A. Rookus,Douglas F. Easton,Antonis C. Antoniou,Lesley McGuffog,D. Gareth Evans,Daniel Barrowdale,Debra Frost,Julian Adlard,Kai-ren Ong,Louise Izatt,Marc Tischkowitz,Ros Eeles,Rosemarie Davidson,Shirley Hodgson,Steve Ellis,Catherine Noguès,Christine Lasset,Dominique Stoppa-Lyonnet,Dominique Stoppa-Lyonnet,Jean-Pierre Fricker,Laurence Faivre,Pascaline Berthet,Maartje J. Hooning,Lizet E. van der Kolk,Carolien M. Kets,Muriel A. Adank,Esther M. John,Wendy K. Chung,Irene L. Andrulis,Irene L. Andrulis,Melissa C. Southey,Mary B. Daly,Saundra S. Buys,Ana Osorio,Christoph Engel,Karin Kast,Rita K. Schmutzler,Trinidad Caldés,Anna Jakubowska,Jacques Simard,Michael Friedlander,Sue-Anne McLachlan,Sue-Anne McLachlan,Eva Machackova,Lenka Foretova,Yen Y. Tan,Yen Y. Tan,Christian F. Singer,Edith Olah,Anne-Marie Gerdes,Brita Arver,Håkan Olsson +67 more
TL;DR: To estimate age-specific risks of breast, ovarian, and contralateral breast cancer for mutation carriers and to evaluate risk modification by family cancer history and mutation location, a large cohort study recruited in 1997-2011 provides estimates of cancer risk based on BRCA1 and BRCa2 mutation carrier status.
Journal ArticleDOI
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore,Nicoletta Colombo,Giovanni Scambia,Byoung Gie Kim,Ana Oaknin,Michael Friedlander,Alla Lisyanskaya,Anne Floquet,Alexandra Leary,Gabe S. Sonke,Charlie Gourley,Susana Banerjee,Amit M. Oza,Antonio González-Martín,Carol Aghajanian,William H. Bradley,Cara Mathews,Joyce F. Liu,Elizabeth S. Lowe,Ralph Bloomfield,Paul DiSilvestro +20 more
TL;DR: The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression‐free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olAParib than with placebo.
Journal ArticleDOI
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan A. Ledermann,Philipp Harter,Charlie Gourley,Michael Friedlander,Ignace Vergote,Gordon J. S. Rustin,Clare L. Scott,Werner Meier,Ronnie Shapira-Frommer,Tamar Safra,Daniela Matei,Euan Macpherson,Claire Watkins,James Carmichael,Ursula A. Matulonis +14 more
TL;DR: Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer and the toxicity profile of olaparIB in this population was consistent with that in previous studies.